
R^{11} is a bond or C_1-C_3 alkylene;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, or phenyl, wherein the C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, or phenyl groups are optionally substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

z is 0 or 1.

In another embodiment, compounds of Formula IV are of the Formula IVb:



(IVb)

or pharmaceutically acceptable salts thereof;

wherein ~~G^1~~ R^5 is independently selected at each occurrence from CH_3, OCH_3, halo, CF_3, CCl_3, CH_2Cl, CCl_2H, CF_2H, CH_2F, and CF_3;

G^2 is H, C_1-C_4 alkyl, or halo;


G^3 is OH, CH_2OH, or CH_2CH_2OH;

G^4 is H, OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, or phenyl, wherein the phenyl group is optionally independently substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

y is 1, 2, or 3.

In an embodiment of Formula IVb, wherein G^1 is independently selected at each occurrence from halo, CF_3, CCl_3, CH_2Cl, CCl_2H, CF_2H, CH_2F, and CF_3;

In another embodiment, compounds of Formula IV are of the Formula IVc:



(IVc)

or pharmaceutically acceptable salts thereof;

wherein X is halo;


~~G^1~~-R^5 is hydrogen or halo;

G^2 is H, C_1-C_4 alkyl, or halo; and

G^4 is H, halo, C_1-C_4 alkyl, or OH.

In one embodiment of Formula IVc, G^2 is C_1-C_4 alkyl or halo, and wherein G^2 is in the 2, 3, or 4 position of the phenyl ring.

In another aspect, provided herein are compounds of the Formula V:



(V)

or pharmaceutically acceptable salts thereof;

wherein

R^4 is H or C_1-C_6 alkyl;

G^1 is H or C_1-C_6 alkyl;


wherein each R^5 is independently selected at each occurrence from the group consisting of -C_1-C_6 alkyl, halo, -CN, -NO_2, -$(L)_m$-OR^8, -$(L)_m$-SR^9, -$(L)_m$-$S(=O)R^9$, -$(L)_m$-$S(=O)_2R^9$, -$(L)_m$-$NHS(=O)_2R^9$, -$(L)_m$-$C(=O)R^9$, -$(L)_m$-$OC(=O)R^9$, -$(L)_m$$CO_2R^8$, -$(L)_m$-$OCO_2R^8$, -$(L)_m$-$CH(R^8)_2$, -$(L)_m$-$N(R^8)_2$, -$(L)_m$-$C(=O)N(R^8)_2$, -$(L)_m$-$OC(=O)N(R^8)_2$, -$(L)_m$-$NHC(=O)NH(R^8)$, -$(L)_m$-$NHC(=O)R^9$, -$(L)_m$-$NHC(=O)OR^9$, -$(L)_m$-$C(OH)(R^8)_2$, -$(L)_m$$C(NH_2)(R^8)_2$, -$C_1$-$C_6$ haloalkyl, -C_1-C_6 dihaloalkyl and -C_1-C_6 trihaloalkyl;

R^{11} is a bond or C_1-C_3 alkylene;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, or phenyl, wherein the C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, or phenyl groups are optionally substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

z is 0 or 1.

In an embodiment, compounds of Formula VI are of the Formula VIa:



(VIa)

or pharmaceutically acceptable salts thereof;

wherein R^5 or G^1 is independently selected at each occurrence from CH_3, OCH_3, halo, CF_3, CCl_3, CH_2Cl, CCl_2H, CF_2H, CH_2F, and CF_3;


G^2 is H, C_1-C_4 alkyl, or halo;

G^3 is OH, CH_2OH, or CH_2CH_2OH;

G^4 is H, OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, or phenyl, wherein the phenyl group is optionally independently substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

y is 1, 2, or 3.

In an embodiment, compounds of Formula VI are of the Formula VIaa:



(VIaa)

or pharmaceutically acceptable salts thereof;

wherein R^5 or G^1 is independently selected at each occurrence from C_1-C_6alkyl, OC_1-C_6alkyl, halo, CF_3, CCl_3, CH_2Cl, CCl_2H, CF_2H, CH_2F, and CF_3;


G^2 is H, C_1-C_4 alkyl, or halo;

G^3 is OH, CH_2OH, or CH_2CH_2OH;

G^4 is H, OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, or phenyl, wherein the phenyl group is optionally independently substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

y is 1, 2, or 3.

In another embodiment, compounds of Formula VI are of the Formula VIb:



(VIb)

or pharmaceutically acceptable salts thereof;


wherein X is halo;

R^5 or G^1 is hydrogen or halo;

G^2 is H, C_1-C_4 alkyl, or halo; and

G^4 is H, halo, C_1-C_4 alkyl, or OH.

In another aspect, provided herein is a compound of Formula VII:



(VII)

or pharmaceutically acceptable salts thereof;

wherein

R^4 is H or C_1-C_6 alkyl;

wherein each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, $-NO_2$, $-(L)_m-SR^9$, $-(L)_m-S(=O)R^9$, $-(L)_m-S(=O)_2R^9$, $-(L)_m-NHS(=O)_2R^9$, $-(L)_m-C(=O)R^9$, $-(L)_m-OC(=O)R^9$, $-(L)_mCO_2R^8$, $-(L)_m-OCO_2R^8$, $-(L)_m-CH(R^8)_2$, $-(L)_m-N(R^8)_2$, $-(L)_m-C(=O)N(R^8)_2$, $-(L)_m-OC(=O)N(R^8)_2$, $-(L)_m-NHC(=O)NH(R^8)$, $-(L)_m-NHC(=O)R^9$, $-(L)_m-NHC(=O)OR^9$, $-(L)_m-C(OH)(R^8)_2$, $-(L)_mC(NH_2)(R^8)_2$, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl and -C_1-C_6 trihaloalkyl;

L is independently, at each occurrence, a bivalent radical selected from -(C_1-C_3 alkylene)-, -(C_3-C_7 cycloalkylene)-, -(C_1-C_3 alkylene)$_m$-O-(C_1-C_3 alkylene)$_m$-, or -(C_1-C_3 alkylene)$_m$-NH-(C_1-C_3 alkylene)$_m$-;

each R^8 is independently, at each occurrence, H, C_1-C_6 alkyl, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, -C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R^2;

R^9 is C_1-C_6 alkyl, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, -C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl,

heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{10} is H, C_1-C_6 alkyl, -$(L)_m$-C(=O)C_1-C_6 alkyl, -$(L)_m$-C(=O)C_3-C_{10} cycloalkyl, -$(L)_m$-C(=O)OC_1-C_6 alkyl, -$(L)_m$-C(=O)OC_3-C_{10} cycloalkyl wherein the alkyl or cycloalkyl groups are optionally substituted with halo, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, or -C_1-C_6 trihaloalkyl;

R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 0-3 substituents selected from R^2;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, and C(O) -C_1-C_6 alkyl;

each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3, or 4;

each occurrence of y is independently selected from the group consisting of 1, 2, and 3;

z' is 0 or 1; and

each occurrence of m is independently 0, 1 or 2.

In one embodiment of Formula VII, each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, -NO_2, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, and -C_1-C_6 trihaloalkyl;

R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 0-3 substituents selected from R^2;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, C(O) -C_1-C_6 alkyl, and C(O) -C_1-C_6 alkoxy.

In an embodiment of Formula VII,


each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;

R^{11} is a bond or C_1-C_3 alkylene;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, and C(O) -C_1-C_6 alkyl, and C(O) -C_1-C_6 alkoxy.

CLAIMS

1. A compound of Formula IV:



(IV)

or pharmaceutically acceptable salts thereof;

wherein

R^4 is H or C_1-C_6 alkyl;

~~wherein each R^5 is independently selected at each occurrence from the group consisting of CH_3, C_1-C_6 alkoxy, halo, -CN, $-NO_2$, $-(L)_m-SR^9$, $-(L)_m-S(=O)R^9$, $-(L)_m-S(=O)_2R^9$, $-(L)_m-NHS(=O)_2R^9$, $-(L)_m-C(=O)R^9$, $-(L)_m-OC(=O)R^9$, $-(L)_mCO_2R^8$, $-(L)_m-OCO_2R^8$, $-(L)_m-N(R^8)_2$, $-(L)_m-C(=O)N(R^8)_2$, $-(L)_m-OC(=O)N(R^8)_2$, $-(L)_m-NHC(=O)NH(R^8)$, $-(L)_m-NHC(=O)R^9$, $-(L)_m-NHC(=O)OR^9$, $-(L)_m-C(OH)(R^8)_2$, $-(L)_mC(NH_2)(R^8)_2$, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl and C_1-C_6 trihaloalkyl;~~

~~L is independently, at each occurrence, a bivalent radical selected from $-(C_1$-C_3 alkylene)-, $-(C_3$-C_7 cycloalkylene)-, $-(C_1$-C_3 alkylene$)_m-O-(C_1$-C_3 alkylene$)_m-$, or $-(C_1$-C_3 alkylene$)_m-NH-(C_1$-C_3 alkylene$)_m-$;~~

~~each R^8 is independently, at each occurrence, H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R^2;~~

~~R^9 is C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl-~~

~~(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R^2;~~

~~R^{10} is OH, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;~~

~~R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 1-3 substituents selected from R^2;~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -CN, $-NO_2$, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, and C(O) C_1-C_6 alkyl;~~

wherein each R^5 is independently selected at each occurrence from the group consisting of CH_3, C_1-C_6 alkoxy, halo, -CN, $-NO_2$, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 and trihaloalkyl;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, C_1-C_6 chloroalkyl, C_1-C_6 dichloroalkyl, C_1-C_6 trichloroalkyl, C_1-C_6 fluoroalkyl, C_1-C_6 difluoroalkyl, C_1-C_6 trifluoroalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 1-3 substituents selected from R^2;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, $-NO_2$, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, C(O) C_1-C_6 alkyl, and C(O) C_1-C_6 alkoxy;

w is 0, 1 or 2;


each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;

each occurrence of y is independently selected from the group consisting of 1, 2, and 3;

each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3; and

each occurrence of m is independently 0, 1 or 2.

2. The compound of claim 1, wherein the compound of Formula IV is of the Formula IVa:



(IVa)

or pharmaceutically acceptable salts thereof.

~~3. The compound of claims 1 or 2, wherein~~

~~each R^5 is independently selected at each occurrence from the group consisting of CH_3, C_1-C_6 alkoxy, halo, -CN, $-NO_2$, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 and trihaloalkyl;~~

~~R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, C_1-C_6 chloroalkyl, C_1-C_6 dichloroalkyl, C_1-C_6 trichloroalkyl, C_1-C_6 fluoroalkyl, C_1-C_6 difluoroalkyl, C_1-C_6 trifluoroalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;~~

~~R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 1-3 substituents selected from R^2;~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, C(O) -C_1-C_6 alkyl, and C(O) -C_1-C_6 alkoxy.~~

43. The compound of ~~any of~~ claims ~~1-3~~ or 2, wherein

each R^5 is independently selected at each occurrence from the group consisting of CH_3, C_1-C_6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, C_1-C_6 fluoroalkyl, C_1-C_6 difluoroalkyl, C_1-C_6 trifluoroalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{11} is a bond or C_1-C_3 alkylene;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, and C(O) -C_1-C_6 alkyl, and C(O) -C_1-C_6 alkoxy.

~~54~~. The compound of any of claims 1-43, wherein R^5 is 3-F, 3-Cl, 3-CH_3, 3-CH_2F, 3-CHF_2, 4-F, 3-CH_3-4-F, 3-Cl-4-F, 3-Br-4-F, 3,4,5-trifluoro, 3,4,5-trichloro, or 3-chloro-4,5-difluoro.

~~65~~. The compound of any of claims 1-~~54~~, wherein w is 1 or 2.


~~76~~. The compound of any of claims 1-~~65~~, wherein

R^{11} is a bond or C_1-C_3 alkylene;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, or phenyl, wherein the C_3-C_{10} cycloalkyl, [[a]] C_3-C_{10} heterocycloalkyl, or phenyl groups are optionally substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

z is 0 or 1.

87. TheA compound of any of claims 1-7, wherein the compound of Formula I is of the Formula IVb:



(IVb)

and pharmaceutically acceptable salts thereof;

wherein G1R5 is independently selected at each occurrence from CH_3, OCH_3, halo, CF_3, CCl_3, CH_2Cl, CCl_2H, CF_2H, CH_2F, and CF_3;


G^2 is H, C_1-C_4 alkyl, or halo;

G^3 is OH, CH_2OH, or CH_2CH_2OH;

G^4 is H, OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, or phenyl, wherein the phenyl group is optionally independently substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

y is 1, 2, or 3.

98. The compound of any of claims 1-87, wherein the compound of Formula IVb is of the Formula IVc:



(IVc)

or pharmaceutically acceptable salts thereof;

wherein X is halo;


~~G^1~~R^5 is hydrogen or halo;

G^2 is H, C_1-C_4 alkyl, or halo; and

G^4 is H, halo, C_1-C_4 alkyl, or OH.

~~10~~9. The compound of any of claims ~~8~~7 or ~~9~~8, wherein G^2 is C_1-C_4 alkyl or halo, and wherein G^2 is in the 2, 3, or 4 position of the phenyl ring.

~~11~~10. A compound of Formula V:



(V)

or pharmaceutically acceptable salts thereof;

wherein

R^4 is H or C_1-C_6 alkyl;

G^1 is H or C_1-C_6 alkyl;

~~wherein each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, halo, CN, NO_2, $(L)_m$-OR^8, $(L)_m$-SR^9, $(L)_m$-$S(=O)R^9$, $(L)_m$-$S(=O)_2R^9$, $(L)_m$-~~

~~$NHS(=O)_2R^9$, $-(L)_m-C(=O)R^9$, $-(L)_m-OC(=O)R^9$, $-(L)_mCO_2R^8$, $-(L)_m-OCO_2R^8$, $-(L)_m-CH(R^8)_2$, $-(L)_m-N(R^8)_2$, $-(L)_m-C(=O)N(R^8)_2$, $-(L)_m-OC(=O)N(R^8)_2$, $-(L)_m-NHC(=O)NH(R^8)$, $-(L)_m-NHC(=O)R^9$, $-(L)_m-NHC(=O)OR^9$, $-(L)_m-C(OH)(R^8)_2$, $-(L)_mC(NH_2)(R^8)_2$, $-C_1-C_6$ haloalkyl, $-C_1-C_6$ dihaloalkyl and $-C_1-C_6$ trihaloalkyl;~~

~~L is independently, at each occurrence, a bivalent radical selected from $-(C_1-C_3$ alkylene)-, $-(C_3-C_7$ cycloalkylene)-, $-(C_1-C_3$ alkylene$)_m-O-(C_1-C_3$ alkylene$)_m-$, or $-(C_1-C_3$ alkylene$)_m-NH-(C_1-C_3$ alkylene$)_m-$;~~

~~each R^8 is independently, at each occurrence, H, C_1-C_6 alkyl, $-C_1-C_6$ haloalkyl, $-C_1-C_6$ dihaloalkyl, $-C_1-C_6$ trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, $-C_1-C_4$ alkyl-(C_3-C_{10} cycloalkyl), $-C_1-C_4$ alkyl-(C_3-C_{10} heterocycloalkyl), $-C_1-C_4$ alkyl-(aryl), or $-C_1-C_4$ alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R^2;~~

~~R^9 is C_1-C_6 alkyl, $-C_1-C_6$ haloalkyl, $-C_1-C_6$ dihaloalkyl, $-C_1-C_6$ trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, $-C_1-C_4$ alkyl-(C_3-C_{10} cycloalkyl), $-C_1-C_4$ alkyl-(C_3-C_{10} heterocycloalkyl), $-C_1-C_4$ alkyl-(aryl), or $-C_1-C_4$ alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -OH, -CN, $-NO_2$, $-C_1-C_6$ alkyl, $-C_1-C_6$ alkoxy, $-C_1-C_6$ fluoroalkyl, $-C_1-C_6$ heteroalkyl, and C(O)-C_1-C_6 alkyl;~~

wherein each R^5 is independently selected at each occurrence from the group consisting of –OH, C_1-C_6 alkyl, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;

each R^2 is independently selected at each occurrence from the group consisting of halo, $-C_1-C_6$ alkyl, or $-C_1-C_6$ alkoxy;

n is 1, 2, 3, 4, 5, or 6;

each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;

each occurrence of y is independently selected from the group consisting of 1, 2, and 3; and

each occurrence of m is independently 0, 1 or 2.

~~12. The compound of claim 11, wherein~~

~~each R^5 is independently selected at each occurrence from the group consisting of OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, $-NO_2$, C_1-C_6 chloroalkyl, C_1-C_6 dichloroalkyl, C_1-C_6 trichloroalkyl, C_1-C_6 fluoroalkyl, C_1-C_6 difluoroalkyl and C_1-C_6 trifluoroalkyl; and~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -OH, -CN, $-NO_2$, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, and C(O)-C_1-C_6 alkyl.~~

~~13. The compound of claims 11 or 12, wherein~~

~~each R^5 is independently selected at each occurrence from the group consisting of OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;~~


~~R^2 is independently selected at each occurrence from the group consisting of OH, halo, -CN, $-NO_2$, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, and C(O)-C_1-C_6 alkyl.~~

~~14. The compound of claims 11, 12, or 13 wherein~~

~~each R^5 is independently selected at each occurrence from the group consisting of OH, C_1-C_6 alkyl, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl; and~~

~~each R^2 is independently selected at each occurrence from the group consisting of halo, C_1-C_6 alkyl, or C_1-C_6 alkoxy.~~

~~15~~11. A compound of Formula VI:



(VI)

or pharmaceutically acceptable salts thereof;

wherein

R^4 is H or C_1-C_6 alkyl;

G^1 is H or C_1-C_6 alkyl;

wherein each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6alkyl, C_1-C_6 alkoxy, halo, -CN, -NO_2, -$(L)_m$-SR^9, -$(L)_m$-$S(=O)R^9$, -$(L)_m$-$S(=O)_2R^9$, -$(L)_m$-$NHS(=O)_2R^9$, -$(L)_m$-$C(=O)R^9$, -$(L)_m$-$OC(=O)R^9$, -$(L)_m$$CO_2R^8$, -$(L)_m$-$OCO_2R^8$, -$(L)_m$-$CH(R^8)_2$, -$(L)_m$-$N(R^8)_2$, -$(L)_m$-$C(=O)N(R^8)_2$, -$(L)_m$-$OC(=O)N(R^8)_2$, -$(L)_m$-$NHC(=O)NH(R^8)$, -$(L)_m$-$NHC(=O)R^9$, -$(L)_m$-$NHC(=O)OR^9$, -$(L)_m$-$C(OH)(R^8)_2$, -$(L)_m$$C(NH_2)(R^8)_2$, -$C_1$-$C_6$ haloalkyl, -C_1-C_6 dihaloalkyl and -C_1-C_6 trihaloalkyl;

L is independently, at each occurrence, a bivalent radical selected from -(C_1-C_3 alkylene)-, -(C_3-C_7 cycloalkylene)-, -(C_1-C_3 alkylene)$_m$-O-(C_1-C_3 alkylene)$_m$-, or -(C_1-C_3 alkylene)$_m$-NH-(C_1-C_3 alkylene)$_m$-;

each R^8 is independently, at each occurrence, H, C_1-C_6 alkyl, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, -C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R^2;

R^9 is C_1-C_6 alkyl, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, -C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, [[a]] C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl-

(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{10} is OH, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, ~~a~~ C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 1-3 substituents selected from R^2;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, and C(O) -C_1-C_6 alkyl;

w is 0, 1 or 2;

each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;

each occurrence of y is independently selected from the group consisting of 0, 1, 2, 3 and 4;

each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3;

each occurrence of m is independently 0, 1 or 2.

~~16~~12. The compound of claim ~~15~~ 11, wherein

each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, -NO_2, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, and -C_1-C_6 trihaloalkyl;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, -C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, ~~a~~ C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 1-3 substituents selected from R^2;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, C(O) -C_1-C_6 alkyl, and C(O) -C_1-C_6 alkoxy.

~~17~~13. The compound of any of claims ~~15-16~~ 11-12, wherein

each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, C_1-C_6 fluoroalkyl, C_1-C_6 difluoroalkyl, C_1-C_6 trifluoroalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, ~~a~~ C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, -C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), -C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), -C_1-C_4 alkyl-(aryl), or -C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;

R^{11} is a bond or C_1-C_3 alkylene;

R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, -C_1-C_6 alkyl, -C_1-C_6 alkoxy, -C_1-C_6 fluoroalkyl, -C_1-C_6 heteroalkyl, and C(O) -C_1-C_6 alkyl, and C(O) -C_1-C_6 alkoxy.

~~18~~14. The compound of any of claims ~~15-17~~ 11-13, wherein R^5 is 3-F, 3-Cl, 3-CH_3, 3-CH_2F, 3-CHF_2, 4-F, 3-CH_3-4-F, 3-Cl-4-F, 3-Br-4-F, 3,4,5-trifluoro, 3,4,5-trichloro, or 3-chloro-4,5-difluoro.

~~19~~15. The compound of any of claims ~~15-18~~ 11-14, wherein w is 1 or 2.


~~20~~16. The compound of any of claims ~~15-19~~ 11-15, wherein R^{11} is a bond or C_1-C_3 alkylene;

R^{10} is OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, C_3-C_{10} cycloalkyl, ~~a~~ C_3-C_{10} heterocycloalkyl, or phenyl, wherein the C_3-C_{10} cycloalkyl, a C_3-C_{10}

heterocycloalkyl, or phenyl groups are optionally substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

z is 0 or 1.

~~21~~17. ~~The~~A compound of ~~any of claims 15-20, wherein the compound of Formula VI is of the~~ Formula VIa:



(VIa)

or pharmaceutically acceptable salts thereof;

wherein R^5 or G^1 is independently selected at each occurrence from CH_3, OCH_3, halo, ~~CF_3,~~ CCl_3, CH_2Cl, CCl_2H, CF_2H, CH_2F, and CF_3;


G^2 is H, C_1-C_4 alkyl, or halo;

G^3 is OH, CH_2OH, or CH_2CH_2OH;

G^4 is H, OH, halo, C_1-C_6 alkyl, C_1-C_6 alkyl-OH, -C_1-C_6 chloroalkyl, -C_1-C_6 dichloroalkyl, -C_1-C_6 trichloroalkyl, -C_1-C_6 fluoroalkyl, -C_1-C_6 difluoroalkyl, -C_1-C_6 trifluoroalkyl, or phenyl, wherein the phenyl group is optionally independently substituted with 1-5 substituents selected from halo, -C_1-C_6 alkyl, and -C_1-C_6 alkoxy; and

y is 1, 2, or 3.

~~22~~18. The compound of any of claims ~~15-21~~17, wherein the compound of Formula VIa is of the Formula VIb:



(VIb)

or pharmaceutically acceptable salts thereof;


wherein X is halo;

R^5 or G^1 is hydrogen or halo;

G^2 is H, C_1-C_4 alkyl, or halo; and

G^4 is H, halo, C_1-C_4 alkyl, or OH.

~~23~~19. A compound of Formula VII:



(VII)

or pharmaceutically acceptable salts thereof;

wherein

R^4 is H or C_1-C_6 alkyl;

~~wherein each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, -NO_2, -$(L)_m$-SR^9, -$(L)_m$-$S(=O)R^9$, -$(L)_m$-$S(=O)_2R^9$, -$(L)_m$-$NHS(=O)_2R^9$, -$(L)_m$-$C(=O)R^9$, -$(L)_m$-$OC(=O)R^9$, -$(L)_m$$CO_2R^8$, -$(L)_m$-$OCO_2R^8$, -$(L)_m$-~~

~~$CH(R^8)_2$, $-(L)_m-N(R^8)_2$, $-(L)_m-C(=O)N(R^8)_2$, $-(L)_m-OC(=O)N(R^8)_2$, $-(L)_m-NHC(=O)NH(R^8)$, $-(L)_m-NHC(=O)R^9$, $-(L)_m-NHC(=O)OR^9$, $-(L)_m-C(OH)(R^8)_2$, $-(L)_mC(NH_2)(R^8)_2$, $-C_1-C_6$ haloalkyl, $-C_1-C_6$ dihaloalkyl and $-C_1-C_6$ trihaloalkyl;~~

~~L is independently, at each occurrence, a bivalent radical selected from $-(C_1-C_3$ alkylene)-, $-(C_3-C_7$ cycloalkylene)-, $-(C_1-C_3$ alkylene$)_m-O-(C_1-C_3$ alkylene$)_m-$, or $-(C_1-C_3$ alkylene$)_m-NH-(C_1-C_3$ alkylene$)_m-$;~~

~~each R^8 is independently, at each occurrence, H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R^2;~~

~~R^9 is C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, C_1-C_6 trihaloalkyl, C_1-C_6 heteroalkyl, C_3-C_{10} cycloalkyl, a C_3-C_{10} heterocycloalkyl, aryl, heteroaryl, C_1-C_4 alkyl-(C_3-C_{10} cycloalkyl), C_1-C_4 alkyl-(C_3-C_{10} heterocycloalkyl), C_1-C_4 alkyl-(aryl), or C_1-C_4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R^2;~~

R^{10} is H, C_1-C_6 alkyl, $-(L)_m-C(=O)C_1-C_6$ alkyl, $-(L)_m-C(=O)C_3-C_{10}$ cycloalkyl, $-(L)_m-C(=O)OC_1-C_6$ alkyl, $-(L)_m-C(=O)OC_3-C_{10}$ cycloalkyl wherein the alkyl or cycloalkyl groups are optionally substituted with halo, $-C_1-C_6$ haloalkyl, $-C_1-C_6$ dihaloalkyl, or $-C_1-C_6$ trihaloalkyl;

~~R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 0-3 substituents selected from R^2;~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -CN, $-NO_2$, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, and C(O)-C_1-C_6 alkyl;~~

wherein each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, $-NO_2$, $-C_1-C_6$ haloalkyl, $-C_1-C_6$ dihaloalkyl, and $-C_1-C_6$ trihaloalkyl;

R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 0-3 substituents selected from R^2;

R^2 is independently selected at each occurrence from the group consisting of H, C_1-C_4 alkyl, or halo;

each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3, or 4;

each occurrence of y is independently selected from the group consisting of 1, 2, and 3;

z' is 0 or 1; and

each occurrence of m is independently 0, 1 or 2.

~~24. The compound of claim 23, wherein~~

~~each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, -CN, -NO_2, C_1-C_6 haloalkyl, C_1-C_6 dihaloalkyl, and C_1-C_6 trihaloalkyl;~~

~~R^{11} is a bond or C_1-C_3 alkylene, wherein the C_1-C_3 alkylene is optionally substituted with 0-3 substituents selected from R^2;~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, C(O) C_1-C_6 alkyl, and C(O) C_1-C_6 alkoxy.~~

~~25~~20. The compound of ~~any of~~ claims ~~23-24~~ 19, wherein

each R^5 is independently selected at each occurrence from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl; and

R^{11} is a bond or C_1-C_3 alkylene~~;~~

~~R^2 is independently selected at each occurrence from the group consisting of halo, -CN, -NO_2, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 fluoroalkyl, C_1-C_6 heteroalkyl, and C(O) C_1-C_6 alkyl, and C(O) C_1-C_6 alkoxy~~.

~~26~~21. The compound of any of claims ~~23-25~~ 19 or 20, wherein R^5 is 3-F, 3-Cl, 3-CH_3, 3-CH_2F, 3-CHF_2, 4-F, 3-CH_3-4-F, 3-Cl-4-F, 3-Br-4-F, 3,4,5-trifluoro, 3,4,5-trichloro, or 3-chloro-4,5-difluoro.

~~27. The compound of any of claims 23-26, wherein R^2 is H, C_1-C_4-alkyl, or halo.~~

~~28~~22. The compound of any of claims ~~23-27~~19-21, wherein R^{10} is $C(=O)C_3$-C_{10} cycloalkyl, wherein the ~~or~~ cycloalkyl group is optionally substituted with halo, -C_1-C_6 haloalkyl, -C_1-C_6 dihaloalkyl, or -C_1-C_6 trihaloalkyl.

~~29~~23. A composition comprising a compound according to any one of claims 1-~~28~~22, or a salt, solvate or N-oxide thereof.

~~30~~24. The composition of claim ~~29~~ 23, wherein the composition is pharmaceutical and further comprises at least one pharmaceutically acceptable carrier.

~~31~~25. Use of a compound according to any one of claims 1-~~28~~22, in the preparation of a medicament for treating, eradicating, reducing, slowing, or inhibiting an HBV infection in an individual in need thereof;
for reducing the viral load associated with an HBV infection in an individual in need thereof;
for reducing reoccurrence of an HBV infection in an individual in need thereof;
for reducing an adverse physiological impact of an HBV infection in an individual in need thereof;
for inducing remission of hepatic injury from an HBV infection in an individual in need thereof;
for reducing the physiological impact of long-term antiviral therapy for HBV infection in an individual in need thereof; or
for prophylactically treating an HBV infection in an individual in need thereof, wherein the individual is afflicted with a latent HBV infection.

~~32~~26. The use of ~~any of~~ claims ~~31~~ 25, further comprising at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~literature-described capsid assembly modulator~~ BAY 41-4109, reverse transcriptase inhibitor, a TLR-agonist, ~~and agents of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-

yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and a combination thereof, for administration to the individual.

~~33~~27. The use of claim ~~32~~ 26, wherein the reverse transcriptase inhibitor is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, ~~PMPA,~~ cidofovir, Efavirenz, Nevirapine, Delavirdine, or Etravirine.

~~34~~28. The use of claim ~~32~~ 26, wherein the TLR-~~7~~agonist is selected from the group consisting of SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl][3-(4-morpholinyl)propyl]amino}methyl)phenyl]acetate).

~~35~~29. The use of claim ~~32~~ 26, wherein the compound and the at least one additional therapeutic agent are co-formulated.

~~36~~30. The use of claim ~~32~~ 26, wherein the compound and the at least one additional therapeutic agent are co-administered.

~~37~~31. The use of claim ~~32~~ 26, wherein administration of the compound allows for administering of the at least one additional therapeutic agent at a lower dose or frequency as compared to the administering of the at least one additional therapeutic agent alone that is required to achieve similar results in prophylactically treating an HBV infection in an individual in need thereof.

~~38~~32. The use of claim ~~32~~ 26, wherein before administration of the therapeutically effective amount of the compound ~~of formula (I)~~ the individual is known to be refractory to a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~distinct capsid assembly modulator~~ BAY 41-4109, ~~antiviral~~

~~compounds of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and combination thereof.

~~39~~33. The use of claim ~~32~~ 26, wherein the administration of the compound reduces viral load in the individual to a greater extent compared to the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~distinct capsid assembly modulator~~ BAY 41-4109, ~~antiviral compounds of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and combination thereof.

~~40~~34. The use of claim ~~32~~ 26, wherein the administration of the compound causes a lower incidence of viral mutation and/or viral resistance than the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~distinct capsid assembly modulator~~ BAY 41-4109, ~~antiviral compounds of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and combination thereof.

~~41~~35. A compound according to any one of claims 1 ~~28~~, 3-10, 11-19, 20, 21 or 22, for use in a method of treating, eradicating, reducing, slowing, or inhibiting an HBV infection in an individual in need thereof; in a method of reducing the viral load associated with an HBV infection in an individual in need thereof; in a method of reducing reoccurrence of an HBV infection in an individual in need thereof; in a method of reducing an adverse physiological impact of an HBV infection in an individual in need thereof; in a method of inducing remission of hepatic injury from an HBV infection in an individual in need thereof; in a method of reducing the physiological impact of long-term antiviral therapy for HBV infection in an

individual in need thereof; or in a method of prophylactically treating an HBV infection in an individual in need thereof, wherein the individual is afflicted with a latent HBV infection.

~~42~~36. The compound of ~~any of~~ claim~~s 41~~35, further comprising at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~literature-described capsid assembly modulator~~ BAY 41-4109, reverse transcriptase inhibitor, a TLR-agonist, ~~and agents of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and a combination thereof, for administration to the individual.

~~43~~37. The compound of claim ~~41~~ 35, wherein the reverse transcriptase inhibitor is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, ~~PMPA,~~ cidofovir, Efavirenz, Nevirapine, Delavirdine, or Etravirine.

~~44~~38. The compound of claim ~~41~~ 35, wherein the TLR-~~7~~ agonist is selected from the group consisting of SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl][3-(4-morpholinyl)propyl]amino}methyl)phenyl]acetate).

~~45~~39. The ~~compund~~ compound of claim ~~41~~ 35, wherein the compound and the at least one additional therapeutic agent are co-formulated.

~~46~~40. The compound of claim ~~41~~ 35, wherein the compound and the at least one additional therapeutic agent are for co-administration.

~~47~~41. The ~~compund~~ compound of claim ~~41~~ 35, wherein administration of the compound allows for administering of the at least one additional therapeutic agent at a lower dose or


frequency as compared to the administering of the at least one additional therapeutic agent alone that is required to achieve similar results in prophylactically treating an HBV infection in an individual in need thereof.

~~48~~42. The ~~compund~~ compound of claim ~~41~~ 35, wherein before administration of the therapeutically effective amount of the compound ~~of formula (I)~~ the individual is known to be refractory to a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~distinct capsid assembly modulator~~ BAY 41-4109, ~~antiviral compounds of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and combination thereof.

~~49~~43. The ~~compund~~ compound of claim ~~41~~ 35, wherein the administration of the compound reduces viral load in the individual to a greater extent compared to the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~distinct capsid assembly modulator~~ BAY 41-4109, ~~antiviral compounds of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and combination thereof.


~~50~~44. The compound of claim ~~41~~ 35, wherein the administration of the compound causes a lower incidence of viral mutation and/or viral resistance than the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, ~~distinct capsid assembly modulator~~ BAY 41-4109, ~~antiviral compounds of distinct or unknown mechanism~~ AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide), and combination thereof.

45. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

46. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

47. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

48. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

49. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

50. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

51. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

52. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

53. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

54. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

55. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

56. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

57. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

58. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

59. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

60. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

61. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

62. The compound of claim 8, wherein the compound of Formula IVc is:




or a pharmaceutically acceptable salt thereof.

63. The compound of claim 8, wherein the compound of Formula IVc is:



or a pharmaceutically acceptable salt thereof.

64. The compound of claim 8, wherein the compound of Formula IVc is:



or a pharmaceutically acceptable salt thereof.